tbuckley/cabot-search huggingface dataset:
PROceeding With the Patient-Reported Outcomes (PROs) Version of the Common Terminology Criteria for Adverse Events
Authors: Benjamin Movsas
Journal: JAMA Oncology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Hormonal Influences on Growth of B16 Murine Melanoma&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: S R Simon, W B Ershler
Journal: JNCI Journal of the National Cancer Institute (1985)

The influence of endocrine factors on B16 melanoma growth was investigated in young and old male mice to test the hypothesis that senescent hormonal changes account for the age-associated reduced tumor growth previously observed in our laboratory. Again it was demonstrated that tumors grow more slowly and to a lesser volume in old mice. For a test of whether senescent hormonal changes account for this tumor growth pattern, B16 was implanted into male and female C57BL/6 mice and tumor growth observed. In addition, young adult male mice were castrated and later B16 melanoma growth was determined. Tumor growth was similar in male and female mice. Contrary to our expectations, however, castrated male mice demonstrated larger tumor volumes, despite serum testosterone levels similar to those of old mice. Furthermore, after iv tumor cell injection, the occurrence of pulmonary colonies was greater in castrated mice. These observations indicate the importance of hormonal factors in this commonly explored tumor system. With regard to aging and tumor growth, however, senescent sex hormone changes probably do not account for the slower tumor growth observed in aged animals.
Cell Cycle Genes in Ovarian Cancer
Authors: Giuseppina D’Andrilli, Christine Kumar, Giovanni Scambia, Antonio Giordano
Journal: Clinical Cancer Research (2004)

Abstract Human malignant tumors are characterized by abnormal proliferation resulting from alterations in cell cycle-regulatory mechanisms. The regulatory pathways controlling cell cycle phases include several oncogenes and tumor suppressor genes that display a range of abnormalities with potential usefulness as markers of evolution or treatment response in ovarian cancer. This review summarizes the current knowledge about these aberrations in malignant tumors of the ovary. We sought to divide cell cycle-regulatory genes into four subgroups on the basis of their predominant role in a specific phase or during the transition between two phases of the cell cycle.
TOWARD CYSTIC FIBROSIS GENE THERAPY
Authors: John A. Wagner, MD, PhD, Phyllis Gardner, MD
Journal: Annual Review of Medicine (1997)

▪ Abstract Cystic fibrosis (CF) is a common genetic disorder characterized by defective epithelial chloride transport and progressive lung disease. Although great strides have been made in the treatment of CF, it remains lethal, often by early adulthood. CF is one of the most extensively researched genetic diseases as a target for gene therapy development. It may also serve as an important model for gene therapy of other diseases. Preclinical and clinical research has lead to the rapid development of a variety of vectors designed to correct the basic defect in CF, including adenovirus, adeno-associated virus, and liposomes. Clinical studies have identified the host immune response and low vector efficiency as key impediments to effective CF gene therapy. Further research promises to refine vector technology and bring CF gene therapy to the bedside.
Isolation and characterization of myosin heavy chain isozymes of the bovine conduction system.
Authors: I Komuro, K Nomoto, T Sugiyama, M Kurabayashi, F Takaku, Y Yazaki
Journal: Circulation Research (1987)

To determine the characteristics of cardiac myosin in the conduction system, a pure Purkinje fiber preparation, consisting of atrioventricular nodes and the ventricular conduction system, was obtained from bovine hearts. Two types of myosin heavy chain isozymes, alpha-type and beta-type, were fractionated by affinity chromotography using monoclonal antibodies CMA19 and HMC50, which are specific for the alpha-type heavy chain and beta-type heavy chain, respectively. Competitive enzyme-linked immunosorbent assay demonstrated that the content of beta-type in the atrioventricular node (30-40%) was higher than that in atrial ordinary myocardium (10-20%) and that of the alpha-type was 30-40% in the ventricular conduction system, which was much higher than that in the ventricular ordinary myocardium (less than 10%). By one- and two-dimensional electrophoresis of the peptides produced by partial and complete digestion, the peptide compositions of alpha-type and beta-type in the conduction system were shown to be very similar to those of alpha-type and beta-type in ordinary myocardium, respectively. The CA2+-activated ATPase activity of myosin of the atrioventricular nodes was lower than that of ordinary atrial myosin (0.46 +/- 0.03 versus 0.58 +/- 0.02 mumol Pi/mg/min, mean +/- SEM, p less than 0.05) and in contrast, that of ventricular specialized myocardium was higher than that of myosin in the ventricular ordinary working myocardium (0.32 +/- 0.03 versus 0.22 +/- 0.01 mumol Pi/mg/min, p less than 0.05). This was in good agreement with the relative proportion of myosin isozymes.(ABSTRACT TRUNCATED AT 250 WORDS)
Feasibility of Sentinel Lymph Node Biopsy in Multiple Unilateral Synchronous Breast Cancer: Results of a French Prospective Multi-Institutional Study (IGASSU 0502).
Authors: S. Giard, N. Penel, M. Chauvet, H. Mignotte, P. Martel, C. Tunon de Lara, P. Gimbergues, P. Dessogne, J. Classe, E. Fondrinier, T. Marmousez, J. Blanchot
Journal: Cancer Research (2009)

Abstract Introduction: Controversy remains over whether to perform sentinel lymph node biopsy (SLNB) in multiple (multicentric or multifocal) unilateral synchronous breast cancer. Several small retro- or prospective studies, included pre- or post-operative (or both) multiple synchronous tumours (MST) have suggested that the test performance of SLNB is similar to that seen in unifocal disease. The purpose of this study was to evaluate the feasibility and accuracy of SLNB in preoperatively diagnosed invasive MST.Patients and Methods: The Interest of Axillary SLNB in Multiple Invasive Breast Cancer (IGASSU) study was a prospective multi-institutional study with initial breast surgery, SLNB, and systematic level I to II axillary lymph node dissection (ALND). Patients eligible for the IGASSU study had an operable invasive MST, defined as two or more physically separate invasive tumours in the same or different breast quadrant. The diagnosis of invasive MST was confirmed histologically in all patients by core needle biopsy before surgery. Detection of sentinel node was performed by using either blue patent or radiocolloide injection or both. Injection sites were subareolar.Statistical Analysis: Sensitivity (Se), negative predictive value (NPV), accuracy (A), false negative rate (FNR) and their 95%-confidence intervals (95%CI) were calculated with a classical 2x2 contingency table. A univariate analysis using odds ratio calculation was performed to identify the risk factors for false negative results.Results: Between March 1, 2006, and August 31, 2007, 216 patients were prospectively included from 16 institutions. Of these patients, 211 were evaluable. The SLNB identified rate were 93.4% (197/211). A mean number of 2.2 SLN (range, 1 to 8, ± 1.4) was successfully excised. The mean number of resected nodes in ALND was 12 (range, 1 to 39, ± 5.7). The FNR was 13.6% (14/103) [95%CI: 7- 20%], Se was 86 .4% (89/103) [95%CI: 79- 93%], NPV was 87% (94/108) [95%CI: 80-93%], A was 92.9% (183/197) [95%CI: 89- 96%]. For the 14 false-negative SN, all had ≤ 3 involved nodes in ALND. Table 1 shows patterns of management of the axilla.Table 1 ALND+ALND-Non-identified SLNB113Identified SLNB+4544Identified SLNB-1494 In a univariate analysis, tumour location (only external location vs other location) was the only clinico-pathological factor influencing the FNR (22% [11-33%] vs 7% [4-10%]), even then median aggregate histological tumour size was smaller in external tumours (17mm [range, 12-80] vs 34mm [range, 8- 90], p=0.016).Conclusion: With a FNR of 13.6% (95%CI: 7-20%), we do not recommend SLNB as a routine procedure for multiple unilateral synchronous breast cancer, even for small tumour foci. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 305.
P73 Epidemiology and long term outcomes of patients with chronic obstructive pulmonary disease admitted to Scottish intensive care units
Authors: N. I. Lone, D. A. McAllister, K. M. Rowan, T. S. Walsh, S. H. Wild, G. D. Murray
Journal: Thorax (2011)

<h3>Introduction</h3> Patients admitted to intensive care units (ICUs) with an exacerbation of chronic obstructive pulmonary disease (COPD) are thought to have poor outcomes. Few studies have reported the impact of ICU admission on long-term outcomes. We aimed to describe the epidemiology of patients admitted to all Scottish ICUs with an exacerbation of COPD, and to ascertain the importance of admission on long-term mortality and hospital readmission rates. <h3>Methods</h3> We used a retrospective cohort design linking the Scottish Intensive Care Society Audit Group national database of ICU admissions to the national Scottish hospital discharges and death registry databases. The study cohort comprised all patients admitted to Scottish ICUs in 2005 aged =35 years with a primary ICU admission diagnosis of COPD, or respiratory infection/sepsis as the primary and COPD as the secondary diagnosis. Mortality was defined as death within 4 years of ICU admission. Logistic regression identified factors independently associated with mortality. Hospital readmission rates for the 3 years prior to and following discharge from the index hospitalisation were calculated. <h3>Results</h3> 249 of 7727 (3.2%) first admission episodes to Scottish ICUs in 2005 were with an exacerbation of COPD. Mean age: 67 years; female: 52%; median admission Simplified Acute Physiology Score II: 35 (IQR 26–45). 83% of patients received mechanical ventilation; 24% required tracheostomy. Mean duration of ICU and hospital stays: 6.9 and 28.0 days, respectively. Mean duration of ventilation: 5.7 days (ICU survivors 5.9, non-survivors 5.2). Mortality at ICU and hospital discharge was 23.8% and 34.7%, respectively. It was 46.4% at 1 year and 66.1% at 4-year spost-ICU admission. Only age (p&lt;0.001) and previous COPD admission (p=0.01) were independently associated with 4-year mortality. The mean hospital readmission rate during the 3-year follow-up period was twice that of the period before index hospitalisation (1.4 vs 0.7 readmissions/person-year for all admissions, 0.7 vs 0.3 for COPD admissions, Abstract P73 figure 1). <h3>Conclusion</h3> This Scottish national cohort had comparable short-term mortality rates to those seen in a general ICU population. The poorer long-term mortality rate and increased readmission rates after hospital discharge may be useful to consider alongside other factors when deciding on ICU admission for patients with COPD.
Immunological activity of photodynamic therapy for genital warts
Authors: B. Giomi, F. Pagnini, A. Cappuccini, B. Bianchi, L. Tiradritti, G. Zuccati
Journal: British Journal of Dermatology (2010)

An increasing body of evidence supports the usefulness of photodynamic therapy (PDT) in the treatment of non-neoplastic pathological conditions, including genital warts. In particular, PDT has demonstrated good clinical cure rates and low recurrence, and is now suggested as a safe alternative means of treating condylomata.To confirm the suitability of aminolaevulinic acid (ALA)-PDT for the treatment of this condition and to investigate the recruitment and significance of immune cells in lesional areas by immunohistochemical analysis at different time intervals after treatment.Fifteen subjects with histologically proven, recalcitrant condylomata acuminata of the penis, urethra, vulva or perianal area underwent several cycles of PDT following ALA application. Biopsies were taken at baseline and at different intervals during the trial, and infiltrating immune cells, CD3, CD4, CD8, CD1a and CD68, were evaluated by double immunocytochemical alkaline phosphatase antialkaline phosphatase (APAAP) staining.Our trial provided a complete cure rate of nine of 15 subjects after five PDT sessions. Perianal lesions showed a particularly rapid remission. While progressing towards total lesion clearance, the immunohistochemical pattern was dominated by dense CD4+ T lymphocytes infiltrating the superficial dermis, accompanied by an accumulation of Langerhans cells. Simultaneously, CD8 began to increase in the lesions of responding patients, and Langerhans cells seemed to migrate towards the dermis. CD68+ macrophages apparently did not participate in the immune inflammatory response.This study, to the best of our knowledge, represents the first attempt to clarify the effect of ALA-PDT on infiltrating immune cells in condylomata acuminata. Our results appear to confirm previously reported clinical data, suggesting that rapid activation of specific immunity in lesional skin, CD4+ T lymphocytes and dendritic cells could be responsible for healing.
Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus
Authors: Christian Dejaco, Christina Duftner, Marco A Cimmino, Bhaskar Dasgupta, Carlo Salvarani, Cynthia S Crowson, Hilal Maradit-Kremers, Andrew Hutchings, Eric L Matteson, Michael Schirmer
Journal: Annals of the Rheumatic Diseases (2010)

Objective To compare current definitions of remission and relapse in polymyalgia rheumatica (PMR) with items resulting from a Delphi-based expert consensus. Methods Relevant studies including definitions of PMR remission and relapse were identified by literature search in PubMed. The questionnaire used for the Delphi survey included clinical (n=33), laboratory (n=54) and imaging (n=7) parameters retrieved from a literature search. Each item was assessed for importance and availability/practicability, and limits were considered for metric parameters. Consensus was defined by an agreement rate of ≥80%. Results Out of 6031 articles screened, definitions of PMR remission and relapse were available in 18 and 34 studies, respectively. Parameters used to define remission and/or relapse included history and clinical assessment of pain and synovitis, constitutional symptoms, morning stiffness (MS), physician's global assessment, headache, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood count, fibrinogen and/or corticosteroid therapy. In the Delphi exercise a consensus was obtained on the following parameters deemed essential for definitions of remission and relapse: patient's pain assessment, MS, ESR, CRP, shoulder and hip pain on clinical examination, limitation of upper limb elevation, and assessment of corticosteroid dose required to control symptoms. Conclusions Assessment of patient's pain, MS, ESR, CRP, shoulder pain/limitation on clinical examination and corticosteroid dose are considered to be important in current available definitions of PMR remission and relapse and the present expert consensus. The high relevance of clinical assessment of hips was unique to this study and may improve specificity and sensitivity of definitions for remission and relapse in PMR.
Imatinib Attenuates Hypoxia-induced Pulmonary Arterial Hypertension Pathology via Reduction in 5-Hydroxytryptamine through Inhibition of Tryptophan Hydroxylase 1 Expression
Authors: Loredana Ciuclan, Martin J. Hussey, Victoria Burton, Robert Good, Nicholas Duggan, Sarah Beach, Peter Jones, Roy Fox, Ieuan Clay, Olivier Bonneau, Irena Konstantinova, Andrew Pearce, David J. Rowlands, Gabor Jarai, John Westwick, Margaret R. MacLean, Matthew Thomas
Journal: American Journal of Respiratory and Critical Care Medicine (2013)

Rationale: Whether idiopathic, familial, or secondary to another disease, pulmonary arterial hypertension (PAH) is characterized by increased vascular tone, neointimal hyperplasia, medial hypertrophy, and adventitial fibrosis. Imatinib, a potent receptor tyrosine kinase inhibitor, reverses pulmonary remodeling in animal models of PAH and improves hemodynamics and exercise capacity in selected patients with PAH.Objectives: Here we use both imatinib and knockout animals to determine the relationship between platelet-derived growth factor receptor (PDGFR) and serotonin signaling and investigate the PAH pathologies each mediates.Methods: We investigated the effects of imatinib (100 mg/kg) on hemodynamics, vascular remodeling, and downstream molecular signatures in the chronic hypoxia/SU5416 murine model of PAH.Measurements and Main Results: Treatment with imatinib reduced all measures of PAH pathology observed in hypoxia/SU5416 mice. In addition, 5-hydroxytryptamine (5-HT) and tryptophan hydroxylase 1 (Tph1) expression were reduced compared with the normoxia/SU5416 control group. Imatinib attenuated hypoxia-induced increases in Tph1 expression in pulmonary endothelial cells in vitro via inhibition of the PDGFR-β pathway. To better understand the consequences of this novel mode of action for imatinib, we examined the development of PAH after hypoxic/SU5416 exposure in Tph1-deficient mice (Tph1−/−). The extensive changes in pulmonary vascular remodeling and hemodynamics in response to hypoxia/SU5416 were attenuated in Tph1−/− mice and further decreased after imatinib treatment. However, imatinib did not significantly further impact collagen deposition and collagen 3a1 expression in hypoxic Tph1−/− mice. Post hoc subgroup analysis suggests that patients with PAH with greater hemodynamic impairment showed significantly reduced 5-HT plasma levels after imatinib treatment compared with placebo.Conclusions: We report a novel mode of action for imatinib, demonstrating TPH1 down-regulation via inhibition of PDGFR-β signaling. Our data reveal interplay between PDGF and 5-HT pathways within PAH, demonstrating TPH1-dependent imatinib efficacy in collagen-mediated mechanisms of fibrosis.
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
Authors: Siamak Daneshmand, Anne K. Schuckman, Bernard H. Bochner, Michael S. Cookson, Tracy M. Downs, Leonard G. Gomella, H. Barton Grossman, Ashish M. Kamat, Badrinath R. Konety, Cheryl T. Lee, Kamal S. Pohar, Raj S. Pruthi, Matthew J. Resnick, Norm D. Smith, J. Alfred Witjes, Mark P. Schoenberg, Gary D. Steinberg
Journal: Nature Reviews Urology (2014)
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
Authors: Francoise Brun-Vezinet, Charles Boucher, Clive Loveday, Diane Descamps, Veronique Fauveau, Jacques Izopet, Don Jeffries, Steve Kaye, Corinne Krzyanowski, Andrew Nunn, Rob Schuurman, Jean-Marie Seigneurin, Catherine Tamalet, Richard Tedder, Jonathan Weber, Gerrit-Jan Weverling
Journal: The Lancet (1997)
A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas
Authors: J. Portnow, S. Suleman, S. A. Grossman, S. Eller, K. Carson
Journal: Neuro-Oncology (2002)

Although dexamethasone is very effective for controlling peritumoral cerebral edema, it is associated with distressing side effects that decrease the quality of life for many patients. One potential mechanism to explain the ability of dexamethasone to repair blood-brain barrier dysfunction is through the inhibition of cyclooxygenase-2 (COX-2). The purpose of this study was to determine in a rat brain tumor model whether SC-236, a selective COX-2 inhibitor, is as effective as dexamethasone. Twenty-nine adult male Fischer 344 rats were implanted with intracerebral 9L gliosarcomas and divided into 3 treatment groups. One group (n = 9) served as controls, another (n = 9) was treated with dexamethasone (3 mg/kg p.o. daily), and a third group (n = 11) received SC-236 (3 mg/kg p.o. daily). A survival study was performed. The median survival in the control group was 16 days, compared with 23 days for the dexamethasone group and 23 days for the COX-2 inhibitor group. Kaplan-Meier analysis on pairwise group comparisons showed improved survival that was statistically significant for each treatment group compared with the control group (log-rank test P = 0.009 for dexamethasone to control and P = 0.005 for COX-2 to control), and no significant difference in survival for the COX-2 compared with dexamethasone (log-rank test P = 0.2). These results suggest that a selective COX-2 inhibitor appears to be as effective as dexamethasone in prolonging survival in a rat brain tumor model.
William Greig Fettes Adams Margaret Hilary Birch Leonard Crome Maurice Henry Handoll Crawford John Thurston
Authors: A W. Robertson
Journal: BMJ (2001)

Then he spent a year as a trainee assistant in general practice in Thornhill, Dumfriesshire, before joining ICI.He worked for the metals, plastics, and dyes divisions in various locations including Huddersfield, Manchester, Fleetwood, and Welwyn Garden City.Bill was one of the first to research the toxic effects of vinyl chloride
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin
Authors: J. Cassidy, C. Twelves, E. Van Cutsem, P. Hoff, E. Bajetta, M. Boyer, R. Bugat, U. Burger, A. Garin, U. Graeven, J. McKendrick, J. Maroun, J. Marshall, B. Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, R.L. Schilsky
Journal: Annals of Oncology (2002)